Jyothy Labs Ltd

Nalanda India Equity Fund Limited has submitted a revised disclosure under SEBI's substantial acquisition regulations concerning its shareholding in Jyothy Labs Limited. The fund's total holding in Jyothy Labs stands at 7.60% (27,940,830 shares) after acquiring an additional 0.84% (3,102,384 shares) through open market trades on September 2, 2026. The total share capital of Jyothy Labs is 367,214,511 shares.

Jyothy Labs Limited announced the grant of 1,46,141 Restricted Stock Units (RSUs) under its Employee Stock Unit Plan 2023. The grant was approved by the Nomination, Remuneration and Compensation Committee (NRCC) on September 4, 2026. These RSUs are exercisable into an equal number of equity shares of face value Re. 1 each. The RSU Plan 2023 was approved by the Board on June 9, 2023, and shareholders on July 25, 2023. The RSUs have a vesting period of 1 to 4 years, subject to performance conditions, and can be exercised within 2 years from vesting.

Nalanda India Equity Fund Limited has filed a disclosure under SEBI's Substantial Acquisition of Shares & Takeovers Regulations, 2011, regarding its shareholding in Jyothy Laboratories Limited. The fund sold 3,102,384 shares, representing 0.85% of the total share capital. Following this disposal, Nalanda India Equity Fund's total holding in Jyothy Laboratories stands at 27,940,830 shares, which is 7.61% of the total share capital.

Jyothy Labs Ltd has received an Environmental, Social, and Governance (ESG) rating of 67 from NSE Sustainability Ratings & Analytics Limited. The rating is based on data pertaining to the financial year 2025-26 and was independently prepared by NSE using publicly available information. The company did not engage NSE for this rating. This ESG score reflects the company's performance across environmental, social, and governance factors.

Jyothy Labs Ltd announced on August 24, 2026, the receipt of an Excise Duty Order from the Commissionerate of Central Goods and Services Tax for the period April 2016 to June 2017. The order demands ₹9.69 crore in excise duty, ₹0.97 crore in penalty, and ₹9.69 crore as redemption fine, plus applicable interest. This is due to a difference in interpretation of HSN classification. The company has a favorable prior ruling on a similar dispute and is filing an appeal. Jyothy Labs does not foresee any material financial or operational impact.

Jyothy Labs Ltd has announced the transfer and assignment of leasehold rights for its manufacturing facility in Jammu to M/s. Aikyam Flexipack Private Limited. The transaction, valued at approximately ₹9.93 crores, is expected to be completed by March 31, 2027, subject to mutually agreed conditions. This move represents a divestment of a specific asset, potentially to streamline operations or focus on core business areas. The company has informed the stock exchanges about this development.

Jyothy Labs Limited announced its unaudited financial results for the quarter ended June 30, 2026 (Q1 FY27). The company reported a revenue of ₹773 crore, a 3.0% value growth year-on-year. Excluding sales from Pril and Fa, revenue grew by 8.1% in value and 5.3% in volume. Operating EBITDA margin stood at 8.4%, impacted by elevated commodity inflation. The Fabric Care segment showed strong growth with 14.1% value growth, while Home Care grew 2.4% excluding Pril sales. The company launched new products like Exo Dishwash Liquid and Maxo Incense Sticks. Despite margin pressures from input costs, Jyothy Labs remains focused on innovation, premiumisation, and cost management for sustainable growth.

Jyothy Labs Limited announced its un-audited financial results for the quarter ended June 30, 2026. The results were approved by the Board of Directors at a meeting held on August 12, 2026, and have undergone a limited review by the statutory auditors. The company has complied with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, in its filing.

Jyothy Labs' standalone Q1 FY27 (quarter ended June 30, 2026) net profit fell 50.8% year-on-year to ₹47.64 Cr from ₹96.79 Cr, even as revenue from operations grew a modest 2.95% YoY to ₹773.40 Cr. Sequentially, PAT dropped 29.4% from ₹67.52 Cr in Q4 FY26 on 7.8% higher revenue — a clear case of margin-led profit erosion rather than a demand problem. EBITDA margin (PBT plus finance cost and depreciation, less other income, over revenue) compressed to 8.36% from 16.53% a year ago and 13.49% last quarter; net margin (PAT/total income) fell to 6.02% from 12.56% YoY. Basic EPS was ₹1.30 versus ₹2.64 in Q1 FY26. The squeeze sits almost entirely on the cost-of-goods line. Cost of materials consumed plus the change in inventories — a combined proxy for net input cost — rose to 58.9% of revenue from 49.3% a year ago, confirming the crude-linked input inflation management flagged on the Q4 FY26 call. By segment, Home Care (which includes the household insecticides business) was hit hardest: segment PBT collapsed 82.4% YoY (and 71.3% QoQ) to ₹8.14 Cr on revenue of ₹280.19 Cr, with segment margin falling to 2.9% from 15.0% a year ago. Fabric Care, the largest segment, grew revenue 14.1% YoY to ₹398.89 Cr but PBT still fell 43.0% to ₹38.33 Cr on the same cost pressure. Personal Care was the one bright spot, PBT up 14.7% YoY to ₹12.67 Cr with margin expanding to 13.4% from 11.8%. Against management's own framing from the Q4 FY26 call — cautiously optimistic on FY27 but explicitly warning of near-term margin pressure from crude-linked input inflation, with a ~4% portfolio price hike initiated in March to offset it, and improving Household Insecticides profitability called out as a specific focus area — this quarter is a mixed read: the margin-pressure warning proved accurate and then some, but the stated aim of improving Household Insecticides/Home Care profitability moved sharply in the wrong direction instead, so the guidance is best read as missed on substance even though the caution itself was directionally correct. No Q1-specific Street consensus could be sourced; the broadest available reference (Trendlyne, 11-analyst consensus) pegs FY27 revenue growth at 6.7% and full-year PAT growth at roughly flat (-0.7%) — a 50.8% YoY PAT decline in the first quarter is materially worse than that full-year bar implies, meaning the remaining three quarters now carry a disproportionate load for the full-year number to hold. The result sets up two things to track into Q2 FY27: whether the March price hike (and any further calibrated increases) begins showing up in margins, since this quarter's numbers suggest it has not yet offset the input-cost run-up; and whether Home Care/Household Insecticides profitability — management's explicitly stated priority — stabilizes after an 82% YoY and 71% QoQ PBT decline this quarter.

Jyothy Labs Limited has announced that its Board of Directors will convene on August 12, 2026. The primary agenda item for this meeting is to consider and approve the Un-audited Financial Results for the quarter ended June 30, 2026. The financial results will be subject to a limited review by the company's statutory auditors. The company has also made this information available on its website.